Regeneron Pharmaceuticals reported a steady finish to 2025, driven by growth in key drugs Dupixent and EYLEA HD. While navigating competitive pressures on its legacy blockbuster, the biotech giant outlined an ambitious 2026 strategy focused on regulatory milestones and a broad clinical pipeline.
Regeneron Pharmaceuticals' shares have softened in recent weeks, lagging behind broader market gains. A deep dive into valuation metrics, including DCF analysis and P/E ratios, suggests the biotech giant may be significantly undervalued. We examine the numbers behind the headlines and what they mean for investors.
The pharmaceutical giant is set to release quarterly results before the bell Wednesday, with Wall Street anticipating another period of blockbuster revenue growth driven by its GLP-1 drugs.
Despite facing near-term pressures from a softer ad market and intensified competition, The Trade Desk's leadership in programmatic advertising and its scalable platform present a compelling case for patient investors eyeing the sector's structural shift.
Elon Musk's SpaceX is set to acquire his artificial intelligence startup xAI in a landmark share exchange, with investors offered 0.1433 SpaceX shares for each xAI share, according to a source familiar with the transaction. The deal underscores Musk's strategy of consolidating his tech empire amid fierce AI competition.
As enterprises rush to modernize infrastructure for AI, MongoDB finds itself in a pivotal position. Strong Atlas growth signals early success, but declining direct sales and fierce competition pose significant risks, creating a high-stakes binary outcome for investors.
Despite intensifying competition from AMD and Broadcom, Nvidia's relentless innovation and dominant market position present a compelling case for its stock to potentially double in value by 2026, targeting a staggering $9 trillion market cap.
With its patented, FDA-recognized compound Niagen®, Niagen Bioscience (NAGE) has carved out a unique and defensible position at the intersection of nutraceuticals and pharmaceuticals. As the cellular health market expands, the company's dual-channel strategy and deep scientific validation present a compelling growth narrative for investors.
Papa John's International has rolled out a revamped Pan Pizza nationwide, marking a significant strategic push to refresh its menu and compete more aggressively in the premium pizza segment. The move underscores the chain's focus on product innovation to drive customer traffic and brand relevance amid fierce industry competition.
A deep dive into the mounting challenges facing Unity Software Inc., from eroding developer trust and fierce competition to financial pressures, as a prominent bear thesis gains traction among investors.
York Space Systems (YSS) launched onto the public market with a strong first-day pop, capitalizing on defense spending trends and a push for scalable satellite manufacturing. Yet, its path is fraught with competition and the financial growing pains typical of a capital-intensive industry.
The Texas-born travel center giant Buc-ee's is renowned for massive stores and spotless restrooms. But its most disruptive industry practice might be its pay scale, which far exceeds typical convenience store wages and fuels intense competition for jobs.
TD Cowen and H.C. Wainwright have raised price targets on KalVista Pharmaceuticals, expressing confidence in its oral hereditary angioedema treatment ahead of the company's fourth-quarter financial results.
AbbVie's stock presents a complex picture for investors, with recent mixed performance contrasting sharply with its robust multi-year returns. As shares trade below consensus targets, the market weighs near-term headwinds against the pharmaceutical giant's proven track record and pipeline potential.
Amid subscription fatigue and market fragmentation, the proposed union of Netflix and Warner Bros. Discovery is framed not as a threat to competition, but as a necessary consolidation to compete with tech giants and refocus value on consumers.
Major European neobanks like Revolut, Monzo, and bunq are renewing their push for a U.S. banking license, betting on regulatory shifts and market potential. Yet, the path is fraught with complexity, geopolitical uncertainty, and fierce competition.
Prediction market platform Myriad partners with crypto prop firm AceTrader, allowing users to bet on the outcomes of a million-dollar trader competition while competing for a share of a $30,000 prize pool.
Merck & Co. is set to report fourth-quarter 2025 results before the bell on Tuesday, with Wall Street anticipating steady growth. The pharmaceutical giant's shares have climbed 13% over the past year, outpacing the broader healthcare sector. All eyes will be on Keytruda's sales trajectory and management's guidance for the year ahead.
Pharmaceutical giant Eli Lilly is investing $3.5 billion to build a new manufacturing facility in rural Pennsylvania, marking its latest move in a massive U.S. expansion aimed at meeting soaring demand for next-generation obesity treatments and capitalizing on reshoring incentives.
The natural foods giant divests its North American snacks portfolio, including Terra chips and Garden of Eatin', to reduce debt and concentrate on core categories like tea, yogurt, and home meal solutions amid intense competition.
